Announcement PDF ASX RELEASE. 15 September 2025 Emyria Completes Sale of Less than Marketable Parcels to Strategic Life Sciences Consortium Sale at premium validates Emyria’s first-mover advantage and national roll-out to deliver third-party funded psychotherapies amidst growing mental health crisis. • 9,124,870 shares sold at premium – Priced at $0.05 per share, a 6.38% premium to the last traded price of $0.047. • Streamlined Share Register – Affected Less than Marketable shareholders able to sell shares with no brokerage fees, allowing cost-effective disposal. Shareholder numbers streamlined, significantly reducing administration costs associated with maintaining a large number of very small shareholders. • Growth Strategy Validated – Sale of shares at premium validates the strong prospects of Emyria’s national rollout, strengthening the Company on the back of landmark agreements with Medibank Private Ltd (ASX: MPL) and Avive Health. • Strategic Investor Participation – The consortium of life sciences investors provides enhanced strategic alignment and strengthens the Company’s shareholder base. Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce the successful completion of its Less than Marketable Parcel Share Sale Facility (Facility)1, resulting in the acquisition of 9,124,870 fully paid ordinary shares (Shares) held by eligible Less than Marketable (LMP) shareholders by a consortium of specialist life sciences investors at a price of $0.05 per Share, representing a 6.38% premium to the Company’s last traded Share price of $0.047 on 12 September. The proceeds of this sale will be distributed directly to eligible LMP shareholders, as soon as practicable. The Company conducted the Facility to allow smaller shareholders the opportunity to sell their Shares without having to use a broker or pay brokerage, providing an opportunity to dispose of their Shares in a cost-effective manner. The Company values all its shareholders; however, it has incurred significant administration costs maintaining a large number of very small shareholders. By facilitating the sale, the Company has reduced the administrative costs associated with maintaining a large number of very small holdings, which is expected to deliver ongoing administrative and corporate efficiencies to support sustainable growth. The acquisition by the consortium at a premium price reflects strong validation of Emyria’s growth trajectory and its strategy to expand a national network of third-party funded mental health treatment clinics. This follows landmark agreements with Medibank Private Emyria ASX Announcement | 15 Sept 2025 ASX RELEASE. Limited (ASX: MPL)2 and Avive Health3, which represent critical steps in scaling access to innovative, evidence-based mental health treatments across Australia. The strategic investors were introduced to Emyria by GBA Capital Pty Ltd. References: 1. 2. 3. See ASX release 18 July 2025 See ASX release 16 June 2025 See ASX release 29 June 2025 This release has been approved by the Chair of Emyria. Greg Hutchinson Executive Chair 1300 436 363 | investors@emyria.com Emyria ASX Announcement | 15 September 2025 2 ASX RELEASE. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: generates Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. informs Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria ASX Announcement | 15 September 2025 3